Several studies have reported that viral infection is closely associated with the onset,
progression, and exacerbation of asthma. The purpose of this review is to summarize the …

Current therapies to mitigate inflammatory responses involved in airway remodeling and
associated pathological features of asthma and chronic obstructive pulmonary disease …

Background: Dupilumab has been shown to be effective in clinical trials for moderate-to-
severe uncontrolled asthma. However, the efficacy of dupilumab in the real world and the …

Background: Over the last few decades, the efficacy of biological therapies for COPD has
been evaluated by different randomized controlled trials (RCTs). Still, the evaluation of real …

Biologic therapies for severe asthma with persistent type 2 inflammation - PMC Back to Top Skip
to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content …

Severe asthma (SA) is still a demanding challenge in clinical practice. Type 2 inflammation
is the most common phenotype in children and adolescents with SA. As a result, anti …

Type 2 dominant inflammation in nasal mucosa is the key underlying pathophysiological
mechanism of allergic rhinitis (AR) and most presentations of chronic rhinosinusitis with …

The co-occurrence of active tuberculosis (TB) in patients with moderate to severe asthma
presents unique therapeutic challenges, particularly with the advent of biologics like …

Background Long-term daily practice data on patient-reported benefits of dupilumab for
atopic dermatitis (AD) remains limited. Objective To evaluate patient-reported outcome …